 |
Primary
Care Diabetes |
| |
Latest issue now available (PCD) |
| |
|
|
Diabetes
guide for London |
| |
84-page PDF [NHS] |
| |
|
|
Thousands
of children revealed to be suffering from diabetes |
| |
The audit, carried out by the Royal College
of Paediatrics and Child Health on behalf of Sir Liam Donaldson,
the Chief Medical Officer, also identified at least 328 children
under 18 with type 2 diabetes, which can be associated with obesity
and usually occurs much later in life (Times, UK) |
| |
|
|
Institution
of Basal-Bolus Therapy at Diagnosis for Children With Type 1
Diabetes Mellitus |
| |
The institution of basal-bolus therapy with
insulin glargine at the time of diagnosis of type 1 diabetes was
associated with improved glycemic control, in comparison with more-conventional
neutral protamine Hagedorn regimens, during the first year after
diagnosis (Pediatrics) |
| |
|
|
Glucose
Control by the Kidney: An Emerging Target in Diabetes |
| |
The sodium-glucose cotransporter SGLT2 (encoded
by the SLC5A2 gene), which is expressed almost exclusively in proximal
tubules, mediates approximately 90% of active renal glucose reabsorption.
This transporter can be blocked by SGLT2 inhibitors, a class of
compound that may prove effective in managing type 2 diabetes (AJKD) |
| |
|
|
ONGLYZA
(Saxagliptin) Cardiovascular Profile Acceptable According to
FDA Advisory Committee |
| |
The U.S. Food and Drug Administration's (FDA)
Endocrinologic and Metabolic Drugs Advisory Committee determined
(by a vote of 10 to 2) that the data supporting the new drug application
for ONGLYZA (saxagliptin) for the treatment of adults with type
2 diabetes were sufficient to rule out unacceptable cardiovascular
risk relative to comparators in the programme (AstraZeneca) |
| |
|
|
Panel:
Diabetes drug seems safe, more study needed |
| |
A federal panel said Wednesday a diabetes drug
from Bristol-Myers Squibb appears free from heart problems seen
with similar drugs but added that long-term studies should be done
after approval to confirm its safety (Washington Post, USA) |
| |
|
|
Amylin
and Lilly to develop diabetes patch |
| |
Drugmakers Eli Lilly & Co.
and Amylin Pharmaceuticals Inc. are developing an adhesive patch
for type 2 diabetes through a partnership with Altea Therapeutics,
Altea said Wednesday (Forbes) |
| |
|
|
Experience
from a behavioural medicine intervention among poorly controlled
adult type 1 diabetes patients |
| |
The programme proved to be feasible in terms
of design and methods. However, no clear pattern was found regarding
predictors or associations of improved metabolic control as the
response to the intervention (Diabetes Research and Clinical Practice) |
| |
|
|
Dapagliflozin
Clinical Trial Results Indicate Improvement In Key Glycemic Measures
In Treatment-Naïve Type 2 Diabetes Patients |
| |
A 12-week, Phase IIb dose-ranging study showed
that dapagliflozin, a novel, selective, sodium glucose co-transporter2
(SGLT2) inhibitor, produced clinically meaningful reductions across
all key glycemic measures studied [glycosylated hemoglobin level
(HbA1c), fasting plasma glucose (FPG), and postprandial plasma
glucose (PPG)] in treatment-naïve type 2 diabetes patients, compared to placebo (PharmaLive) |
| |
|
